6.82
1.04%
+0.07
アフターアワーズ:
6.82
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 15.4% in April - Defense World
Defense World
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High at $6.95 - MarketBeat
MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
MarketBeat
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for - Yahoo Singapore News
Yahoo Singapore News
Is a Surprise Coming for Amneal (AMRX) This Earnings Season? - Yahoo Movies Canada
Yahoo Movies Canada
Amneal Pharmaceuticals (NYSE:AMRX) shareholders have endured a 88% loss from investing in the stock five years ago - Yahoo Canada Shine On
Yahoo Canada Shine On
Amneal Pharmaceuticals (AMRX) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday? - MSN
MSN
Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Singapore News
Yahoo Singapore News
LSV Asset Management Lowers Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
MarketBeat
Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher - Yahoo New Zealand News
Yahoo New Zealand News
The Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00 - Defense World
Defense World
Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher - Yahoo News UK
Yahoo News UK
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
Benzinga
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts - Amneal Pharmaceuticals (NASDAQ:AMR - Benzinga
Benzinga
Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Movies Canada
Yahoo Movies Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High at $6.90 - Defense World
Defense World
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $7.31 Consensus Price Target from Brokerages - Defense World
Defense World
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) - Simply Wall St
Simply Wall St
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Drugmaker Amneal agrees to $270 million U.S. opioid settlement - MSN
MSN
Amneal stock climbs on Q1 report, opioid settlement update (NASDAQ:AMRX) - Seeking Alpha
Seeking Alpha
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Zacks Investment Research
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? - MSN
MSN
Amneal: Q1 Earnings Snapshot - Press of Atlantic City
Press of Atlantic City
Amneal shares up nearly 4% on better-than-expected Q1 results - Investing.com India
Investing.com India
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Amneal Reports First Quarter 2024 Financial Results - Business Wire
Business Wire
Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement - Amneal Pharmaceuticals (N - Benzinga
Benzinga
ACAD: Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now - StockNews.com
StockNews.com
Mackenzie Financial Corp Has $110000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Defense World
Drug Company Can't Escape Texas Counties' Opioid MDL - Law360
Law360
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
MarketBeat
California is joining with a New Jersey company to make a generic opioid overdose reversal drug - ABC27
ABC27
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Zacks Investment Research
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? - Zacks Investment Research
Zacks Investment Research
FDA approves Amneal's generic version of OTC Narcan (NASDAQ:AMRX) - Seeking Alpha
Seeking Alpha
Marquis Who's Who Honors Ravi D. Patel for Expertise in the Pharmaceutical Industry - 24-7 Press Release
24-7 Press Release
Naresh Gaur, Sr VP - Manufacturing Operations, Amneal Pharma - Express Pharma
Express Pharma
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine - Business Wire
Business Wire
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St
Simply Wall St
Amneal to Report First Quarter 2024 Results on May 3, 2024 - Business Wire
Business Wire
Amneal to Report First Quarter 2024 Results on May 3, 2024 - Yahoo Finance UK
Yahoo Finance UK
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Zacks Investment Research
Bausch Health files patent lawsuit against Amneal Pharma for its liver disease drug - The Financial Express
The Financial Express
Bausch Health sues Amneal over Xifaxan generic (NASDAQ:AMRX) - Seeking Alpha
Seeking Alpha
Bausch Health Sues Amneal Over IBS Treatment Patent - MarketWatch
MarketWatch
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Business Wire
Business Wire
大文字化:
|
ボリューム (24 時間):